{"version":"1.0","type":"link","title":"[Expert consensus on adverse reaction management of PAM pathway inhibitors in breast cancer (2026 edition)].","author_name":"","author_url":null,"provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/82888","thumbnail_width":1200,"thumbnail_height":630}